Normal thyrotrophin response to intravenous thyrotrophin releasing hormone administration: the best index of optimal @entity1955 therapy in XXXX .

@entity1 @entity1375 @entity1955 @entity2016 @entity1218
Normalization of basal thyrotrophin (TSH) level is used as the endpoint in @entity1955 ( @entity2016 ) therapy of @entity1375 . However, several reports have questioned the reliability of this index because of seasonal variation of TSH. Therefore, we studied 85 consecutive @entity1 with @entity1375 over a period of 3.5 y. In these @entity1 , TSH response (delta TSH) to intravenous thyrotrophin releasing hormone ( @entity1218 ) administration was examined when basal TSH was normalized with @entity2016 therapy. Eight @entity1 showed a blunted response (delta TSH less than 5 microU), whereas 27 @entity1 demonstrated an exaggerated response (delta TSH greater than 25 microU). Thus, 42% of @entity1 were apparently on inappropriate @entity2016 dosage. These abnormal TSH responses normalized on adjusting the @entity2016 dosage alone; prolonged therapy with the same dose failed to normalize TSH responses. Minor seasonal variations of basal TSH were observed in 30% of @entity1 . However, TSH response to @entity1218 remained normal. Hence, no adjustment of @entity1955 dose was required. This study, therefore, demonstrates that normalization of TSH response to @entity1218 administration rather than basal TSH may be the best index of adequate @entity1955 therapy in @entity1375 .
